Transcutaneous Auricular Vagus Nerve Stimulation in Psoriatic Arthritis
ConditionPsoriatic Arthritis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMarmara University
About this trial
This prospective single-center interventional study aims to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on disease activity, pain, quality of life, autonomic dysfunction symptoms, and inflammatory biomarkers in patients with psoriatic arthritis (PsA). Participants diagnosed with PsA according to the Classification Criteria for Psoriatic Arthritis (CASPAR) will undergo non-invasive auricular vagus nerve stimulation using the Vagustim device. Clinical outcomes including the Disease Activity Index for Psoriatic Arthritis (DAPSA), Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pain scores, sleep quality, quality of life, anxiety/depression, and inflammatory markers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) will be evaluated before and after treatment.
Eligibility criteria
Qualifiers
Diagnosis of psoriatic arthritis according to the CASPAR criteria
Age between 18 and 65 years
Stable treatment regimen for at least 12 weeks prior to enrollment
Visual Analog Scale (VAS) pain score ≥4 on a 0-10 scale
Disqualifiers
Presence of an implanted cardiac device (e.g., pacemaker, implantable cardioverter-defibrillator) or implanted neurostimulator
History of epilepsy or other uncontrolled neurological disorders
Active severe infection or immunosuppressive condition (e.g., sepsis)
Pregnancy or breastfeeding
Trial design
Treatments tested in this trial
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov